Cohance Lifesciences Limited , formerly known as Suven Pharmaceuticals Limited, has witnessed a significant change in its shareholding structure. Jusmiral Holdings Limited, a promoter of the company, has sold a substantial portion of its stake in an on-market transaction.

Key Details of the Transaction

• Sale Date: September 18, 2025
• Shares Sold: 3,41,48,000
• Stake Reduction: From 33.08% to 24.15%

Impact on Shareholding

The sale has resulted in a notable decrease in Jusmiral Holdings' ownership of Cohance Lifesciences. Here's a breakdown of the changes:

Purpose of Share Sale

According to the disclosure, the proceeds from this share sale will be primarily utilized for the partial repayment of borrowings under a Notes Purchase Agreement dated May 29, 2024. This move suggests that Jusmiral Holdings is taking steps to manage its debt obligations.

Regulatory Compliance

The transaction was disclosed in compliance with SEBI Takeover Regulations. It involved the release of certain encumbrances related to disposal restrictions on the shares. These restrictions were part of covenants under the Notes Purchase Agreement, which included:

1. Maintenance of certain financial ratios
2. Restrictions on disposal and creation of security on Jusmiral Holdings' shareholding in Cohance Lifesciences

About Cohance Lifesciences Limited

Cohance Lifesciences Limited, previously operating as Suven Pharmaceuticals Limited, is a publicly traded company.

This significant reduction in promoter shareholding may have implications for the company's ownership structure and could potentially impact its strategic direction. Investors and market analysts will likely be watching closely for any further developments or changes in the company's management and operations following this transaction.

Cohance Lifesciences , a prominent player in the pharmaceutical sector, witnessed a significant change in its shareholding pattern as one of its promoters, Jusmiral Holdings Limited, sold a substantial portion of its stake on September 18, 2025.

Key Details of the Transaction

• Shares Sold: 3,41,48,000
• Transaction Date: September 18, 2025
• Mode of Sale: On-market transaction through the National Stock Exchange of India Limited
• Sale Proceeds: ₹3093.81 crore

Impact on Shareholding

The sale has resulted in a notable reduction in Jusmiral Holdings' stake in Cohance Lifesciences:

Purpose of the Sale

According to the disclosure made by Jusmiral Holdings Limited, the proceeds from this share sale will be primarily utilized for:

• Part payment of borrowings under a Notes Purchase Agreement
• This agreement was previously disclosed on May 9, 2025

Regulatory Compliance

The transaction and subsequent disclosure were made in compliance with:

1. SEBI's Prohibition of Insider Trading Regulations, 2015
2. Regulation 7(2) read with Regulation 6(2) – Continual Disclosure

Jusmiral Holdings Limited, based in Cyprus, promptly informed Cohance Lifesciences of the transaction. The company, in turn, notified both the BSE Limited and the National Stock Exchange of India Limited, adhering to regulatory requirements.

Company Background

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited, operates in the pharmaceutical sector. The company's shares are traded on the National Stock Exchange of India Limited and the BSE Limited.

This significant reduction in promoter holding may attract investor attention and could potentially impact the stock's trading patterns in the coming days.